Loading
Adding abiraterone to hormone therapy at the time of diagnosis of high-risk metastatic prostate cancer cut deaths by more than a third, establishing early intensification instead of waiting for castration resistance.
Phase 3 placebo-controlled trial of 1,199 men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (at least two of Gleason 8 or more, three or more bone lesions, visceral metastases) randomised to androgen deprivation with abiraterone plus prednisone or placebo.
At the first analysis overall survival at three years was 66 versus 49 percent (hazard ratio 0.62) and radiographic progression-free survival 33.0 versus 14.8 months; the final analysis showed median survival of 53.3 versus 36.5 months.
Abiraterone with androgen deprivation is a standard first-line doublet for metastatic hormone-sensitive prostate cancer, consistent with the STAMPEDE result.
Shares Phase 1 trial of abiraterone acetate confirms that castration-resistant prostate cancer commonly remains hormone driven, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, New England Journal of Medicine, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, New England Journal of Medicine.
Shares Metastatic hormone-sensitive prostate cancer, Prednisone, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, New England Journal of Medicine, Prostate cancer.
Shares Phase 1 trial of abiraterone acetate confirms that castration-resistant prostate cancer commonly remains hormone driven, Prednisone, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, New England Journal of Medicine.
Shares Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, New England Journal of Medicine, Prostate cancer.
Shares Prednisone, Prostate cancer.
Shares Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, New England Journal of Medicine.